IntraBio Inc.

Stories

Shionogi acquires rare disease biotech IntraBio in $2 billion deal

As of October 2026: To become a wholly owned subsidiary of Shionogi Inc.

Shionogi agreed to pay $2 billion for IntraBio, a Texas biotech whose single marketed drug treats two inherited neurological disorders. The deal, announced October 5, hands the Osaka-based drugmaker a product that weeks earlier became the first approved treatment for ataxia-telangiectasia, a rare and fatal genetic disease.

Updated Oct 9

FDA approves AQNEURSA, first treatment for ataxia-telangiectasia

New Capabilities

As of September 2026: Developer and manufacturer of AQNEURSA; holds two FDA-approved indications

About 1 in 40,000 people are born with ataxia-telangiectasia, a genetic disease that destroys the cerebellum and progressively strips muscle control, typically starting in early childhood. Until this week, no drug was approved for it anywhere in the world. IntraBio's AQNEURSA (levacetylleucine) just became the first.

Updated Sep 21